Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541955 | 0.87 | EDNRA (0.50) | EDNRAALDH1A1L3MBTL1HSD11B1USP2 | |
| SCHEMBL6542734 | 0.85 | EDNRA (0.40) | EDNRAPTGESALDH1A1L3MBTL1HSD11B1 | |
| SCHEMBL6542423 | 0.85 | EDNRA (0.57) | EDNRAALDH1A1L3MBTL1USP2LMNA | |
| SCHEMBL6542556 | 0.84 | EDNRA (0.37) | EDNRAPTGESALDH1A1L3MBTL1HSD11B1 | |
| SCHEMBL6541543 | 0.80 | LMNA (0.52) | ALDH1A1L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL6541888 | 0.80 | HSD11B1 (0.42) | PTGESHSD11B1USP2LMNAKDM4E | |
| SCHEMBL6541343 | 0.78 | EDNRA (0.36) | EDNRAPTGESALDH1A1L3MBTL1HSD11B1 | |
| SCHEMBL6542071 | 0.77 | EDNRA (0.58) | EDNRAALDH1A1L3MBTL1USP2HTT | |
| SCHEMBL6541383 | 0.76 | EDNRA (0.57) | EDNRAALDH1A1L3MBTL1USP2HTT | |
| SCHEMBL6542005 | 0.75 | EDNRA (0.56) | EDNRAALDH1A1L3MBTL1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1009743-B1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER LAMBERT CO (US) | 2004-06-30 | — | — | EP | claimed |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2001-11-01 | — | — | US | claimed |
| US-6265399-B1 | ALKYLATION; CYCLIZATION | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | EDNRA 2/4885PTGES 399/4885ALDH1A1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.